The definitive reference for researchers studying MOTS-C — the mitochondrially-encoded peptide that activates AMPK and produces exercise-like metabolic effects. Covers origin, mechanism, aging biology, and research applications.
MOTS-C (Mitochondrial Open reading frame of the twelve S rRNA-c) is a 16-amino acid peptide first described in 2015 by Lee et al. in the journal Cell. What distinguishes MOTS-C fundamentally from almost every other peptide studied in biology is its origin: it is encoded not by nuclear DNA, but by the mitochondrial genome — specifically within the 12S ribosomal RNA gene.
This makes MOTS-C a "mitokine" — a category of signaling molecules secreted by mitochondria to communicate the organelle's metabolic state to the rest of the cell and to distant tissues via the bloodstream. In healthy, metabolically active cells, mitochondria secrete MOTS-C as a signal of energy abundance and proper function. When mitochondrial function declines — as occurs with aging, metabolic disease, or prolonged inactivity — MOTS-C levels fall correspondingly.
Circulating MOTS-C levels in humans decline significantly with age, with studies showing substantially lower plasma concentrations in elderly populations compared to young adults. This age-related decline correlates with increased insulin resistance, reduced mitochondrial biogenesis, and the metabolic deterioration associated with aging — making MOTS-C a research compound of direct relevance to longevity biology and metabolic disease models.
Research Use Only: Corevanta's MOTS-C is sold exclusively for laboratory and scientific research. It is not an approved drug, not a dietary supplement, and is not intended for human consumption or therapeutic use.
MOTS-C's primary mechanism is activation of AMPK — AMP-activated protein kinase — the master cellular energy sensor. AMPK is activated when the cellular AMP:ATP ratio rises (indicating energy depletion, as occurs during exercise or metabolic stress). Once active, AMPK orchestrates a coordinated response to restore energy balance: increasing glucose uptake, stimulating fatty acid oxidation, inhibiting energy-consuming anabolic processes, and promoting mitochondrial biogenesis.
MOTS-C achieves AMPK activation through at least two complementary pathways. First, it inhibits the folate cycle and de novo purine synthesis in the one-carbon metabolism pathway, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — an endogenous AMPK activator. Second, MOTS-C may directly regulate mitochondrial function by modulating the electron transport chain, altering AMP:ATP ratios that activate AMPK through canonical sensing mechanisms.
| Mechanism | Effect | Research Relevance |
|---|---|---|
| AMPK activation | Improved insulin sensitivity + glucose uptake | Metabolic disease, T2D models |
| Folate cycle inhibition | AICAR accumulation → secondary AMPK activation | Metabolic regulation mechanism |
| FOXO1 regulation | Gluconeogenesis suppression in liver | Glucose homeostasis research |
| Mitochondrial biogenesis | PGC-1α signaling, mitochondrial mass | Aging, energy metabolism |
| BBB crossing | CNS AMPK activation and neurological effects | Brain aging, neuroprotection |
A further secondary mechanism involves FOXO1 — a transcription factor that drives hepatic gluconeogenesis (glucose production from non-carbohydrate sources). MOTS-C suppresses FOXO1 activity in the liver, reducing excessive glucose output — a key driver of fasting hyperglycemia in insulin-resistant states. This makes MOTS-C relevant to both muscle-centric insulin sensitivity research and hepatic glucose metabolism models.
The "exercise mimetic" classification reflects MOTS-C's ability to produce metabolic effects that overlap substantially with those observed after aerobic exercise — even in the absence of physical activity. During exercise, AMPK is activated throughout skeletal muscle, liver, and adipose tissue, triggering the same cascade of glucose uptake, fat oxidation, and mitochondrial biogenesis that MOTS-C produces pharmacologically.
Published mouse data (2021, Kim et al.) showed that MOTS-C administration restored insulin sensitivity in 12-month-old (aged) mice on a high-fat diet to levels comparable to young, lean mice — without exercise intervention. This is one of the strongest published demonstrations of exercise-mimetic effects by any peptide compound.
The exercise-mimetic characterization is particularly relevant for aging biology research, where declining physical capacity often accompanies metabolic deterioration. MOTS-C offers a research model for studying what AMPK-driven metabolic improvement looks like in the absence of the confounding variable of exercise intensity and compliance — a clean mechanistic dissection that is difficult to achieve in exercise studies alone.
Additionally, MOTS-C levels in humans are acutely elevated by exercise — suggesting it is part of the body's natural post-exercise signaling cascade. Exogenous MOTS-C administration in research models may be conceptualized as amplifying or restoring this natural mitochondrial communication system.
MOTS-C is studied across a range of metabolic and aging-related research areas:
Corevanta's MOTS-C is provided as a lyophilized (freeze-dried) powder in sealed borosilicate glass vials.
Corevanta's MOTS-C is manufactured to ≥99% purity (HPLC), with LC-MS mass identity confirmation and a third-party certificate of analysis (COA) included with every order. Available in 10mg lyophilized vials.